The Effect of Bifidobacterium animalis subsp. lactis MN-Gup on Glucose Metabolism, Gut Microbiota, and Their Metabolites in Type 2 Diabetic Mice

Chao Zhang,Bing Fang,Nana Zhang,Qi Zhang,Tianjiao Niu,Liang Zhao,Erna Sun,Jian Wang,Ran Xiao,Jingjing He,Shusen Li,Juan Chen,Jie Guo,Wei Xiong,Ran Wang
DOI: https://doi.org/10.3390/nu16111691
IF: 5.9
2024-05-30
Nutrients
Abstract:Probiotics have garnered increasing attention as a potential therapeutic approach for type 2 diabetes mellitus (T2DM). Previous studies have confirmed that Bifidobacterium animalis subsp. lactis MN-Gup (MN-Gup) could stimulate the secretion of glucagon-like peptide-1 (GLP-1) in NCI-H716 cells, but whether MN-Gup has a hypoglycemic effect on T2DM in vivo remains unclear. In this study, a T2DM mouse model was constructed, with a high-fat diet and streptozotocin in mice, to investigate the effect of MN-Gup on diabetes. Then, different doses of MN-Gup (2 × 109 CFU/kg, 1 × 1010 CFU/kg) were gavaged for 6 weeks to investigate the effect of MN-Gup on glucose metabolism and its potential mechanisms. The results showed that a high-dose of MN-Gup significantly reduced the fasting blood glucose (FBG) levels and homeostasis model assessment-insulin resistance (HOMA-IR) of T2DM mice compared to the other groups. In addition, there were significant increases in the short-chain fatty acids (SCFAs), especially acetate, and GLP-1 levels in the MN-Gup group. MN-Gup increased the relative abundance of Bifidobacterium and decreased the number of Escherichia-Shigella and Staphylococcus. Moreover, the correlation analysis revealed that Bifidobacterium demonstrated a significant positive correlation with GLP-1 and a negative correlation with the incremental AUC. In summary, this study demonstrates that Bifidobacterium animalis subsp. lactis MN-Gup has significant hypoglycemic effects in T2DM mice and can modulate the gut microbiota, promoting the secretion of SCFAs and GLP-1.
nutrition & dietetics
What problem does this paper attempt to address?
The paper aims to explore the effects of Bifidobacterium longum subsp. infantis MN-Gup (hereinafter referred to as MN-Gup) on glucose metabolism, gut microbiota, and their metabolites in type 2 diabetic mice. Specifically, the study attempts to answer the following questions: 1. **Does MN-Gup have a hypoglycemic effect?** Previous studies have confirmed that MN-Gup can stimulate NCI-H716 cells to secrete glucagon-like peptide-1 (GLP-1), but its hypoglycemic effect in type 2 diabetes in vivo remains unclear. 2. **What is the impact of different doses of MN-Gup on glucose metabolism in type 2 diabetic mice?** The study used two different doses of MN-Gup (2 × 10^9 CFU/kg and 1 × 10^10 CFU/kg) for intervention and observed their effects on glucose metabolism. 3. **How does MN-Gup regulate the gut microbiota?** The study examined the impact of MN-Gup on the structure of the gut microbiota, particularly its promoting effect on beneficial bacteria such as Bifidobacterium and its inhibitory effect on harmful bacteria such as Escherichia coli-Shigella and Staphylococcus aureus. 4. **Can MN-Gup promote the secretion of short-chain fatty acids (SCFAs) and GLP-1?** The study also explored the impact of MN-Gup on the levels of short-chain fatty acids and GLP-1 to reveal its potential hypoglycemic mechanism. In summary, this paper systematically evaluates the effects of MN-Gup on glucose metabolism, gut microbiota, and metabolites by establishing a type 2 diabetic mouse model, aiming to provide new potential methods for the treatment of type 2 diabetes.